13F Holdings
中文EN

CKDXF Opthea Ltd IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1815620 · Fiscal year ends 06/30

Financial factors as of 2023-06-30 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.1%
TTM net income YoY-53.5%
TTM EPS YoY-22.0%
Revenue 3-yr CAGR22.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-138,912.0%
Net margin-131,963.9%
FCF margin-111,694.4%
EBITDA margin-138,896.3%

Returns

ROE-676.7%
ROA-179.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets105.9%
Debt / equity—
Current ratio5.25x
Interest coverage-11.14x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue20.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30FY20212021-06-30
Income statement
Revenue$25,000$125,000$108,000$90,683$68,613
R&D expense$126.83M$176.33M$128.83M$81.45M$25.89M
Operating income-$155.76M-$191.84M-$150.03M-$96.54M—
Interest expense$46.46M$30.26M$13.46M$0$5,782
Pretax income-$169.74M-$229.65M-$148.45M-$99.12M-$50.28M
Income tax-$6.95M-$9.41M-$5.93M-$6.30M-$4.94M
Net income-$162.79M-$220.24M-$142.52M-$92.82M-$45.34M
EBITDA-$155.75M-$191.82M-$150.01M-$96.53M—
EPS (basic)-0.13-0.35-0.32-0.26-0.14
EPS (diluted)-0.13-0.35-0.32-0.26-0.14
Weighted avg. shares (diluted)1.22B638.20M442.64M351.56M320.43M
Balance sheet
Cash & equivalents$48.44M$172.47M$89.19M$44.63M$118.19M
Receivables$419,000$1.43M$636,564$257,668$565,286
Current assets$56.80M$188.19M$98.39M$59.91M$138.12M
PP&E, netmay include right-of-use assets (IFRS)$0$48,000$33,035$28,082$23,259
Total assets$56.80M$188.79M$98.64M$60.05M$138.41M
Current liabilities$257.87M$64.06M$18.74M$12.04M$3.11M
Short-term debt$9.74M$38.06M$17.84M$11.40M$2.42M
Total liabilities$257.87M$264.60M$104.49M$12.07M$3.12M
Shareholders' equity-$201.07M-$75.81M-$5.85M$47.98M$135.29M
Cash flow statement
Operating cash flow-$158.64M-$161.01M-$120.61M-$71.33M-$45.55M
Capital expenditure$13,000$33,000$22,000$16,910$12,702
Free cash flow-$158.66M-$161.05M-$120.63M-$71.35M-$45.56M
Investing cash flow-$13,000-$33,000-$22,000-$16,910$656,482
Financing cash flow$34.77M$243.73M$167.28M$171,597$116.94M
Depreciation & amortization$7,000$19,000$17,000$11,917$15,012
Stock-based compensation$6.13M$5.08M$5.83M$5.25M$3.90M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.